Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid

References

• Zometa (zoledronic acid) [package insert] (2011) Novartis Pharmaceuticals Corporation, East Hanover, NJ.
   Google Scholar
• Xgeva (denosumab) [package insert] (2010) Amgen Inc., Thousand Oaks, CA.
   Google Scholar
• Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118:1192 - 201; http://dx.doi.org/10.1002/cncr.26313; PMID: 21987386
   PubMed Web of Science ®Google Scholar
• Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188 - 94; http://dx.doi.org/10.1093/annonc/mdq217; PMID: 20444845
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, et al, Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840 - 9; http://dx.doi.org/10.1016/S1470-2045(08)70204-3; PMID: 18718815
   PubMed Web of Science ®Google Scholar
• Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012; 12:40 - 8; http://dx.doi.org/10.1016/j.clbc.2011.08.002; PMID: 22014381
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875 - 82; http://dx.doi.org/10.1200/JCO.2008.16.3832; PMID: 18725648
   PubMed Web of Science ®Google Scholar
• Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 2010; 95:559 - 66; http://dx.doi.org/10.1210/jc.2009-1366; PMID: 20022990
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47:683 - 9; http://dx.doi.org/10.1016/j.ejca.2010.11.024; PMID: 21324674
   PubMed Web of Science ®Google Scholar
• Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94:164 - 70; http://dx.doi.org/10.1111/j.1464-4096.2004.04831.x; PMID: 15217454
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62:6538 - 44; PMID: 12438248
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13:4482 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-07-0551; PMID: 17671133
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055 - 61; http://dx.doi.org/10.1124/jpet.102.035295; PMID: 12183663
   PubMed Web of Science ®Google Scholar
• Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009; 9:791 - 800; http://dx.doi.org/10.2174/156800909789760285; PMID: 20025567
   PubMed Web of Science ®Google Scholar
• Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010; 11:141 - 54; http://dx.doi.org/10.1517/14656560903485664; PMID: 20001436
   PubMed Web of Science ®Google Scholar
• Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9:Suppl 4 3 - 13; http://dx.doi.org/10.1634/theoncologist.9-90004-3; PMID: 15459425
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584 - 93; http://dx.doi.org/10.1038/nrc867; PMID: 12154351
   PubMed Web of Science ®Google Scholar
• Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009; 9:626 - 38; http://dx.doi.org/10.2174/156800909789057033; PMID: 19508172
   PubMed Web of Science ®Google Scholar
• Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182:509 - 15, discussion 515-6; http://dx.doi.org/10.1016/j.juro.2009.04.023; PMID: 19524963
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564 - 71; http://dx.doi.org/10.1200/JCO.2008.19.2146; PMID: 19237632
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132 - 9; http://dx.doi.org/10.1200/JCO.2010.29.7101; PMID: 21060033
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337 - 42; http://dx.doi.org/10.1038/nature01658; PMID: 12748652
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88:Suppl 2961 - 78; http://dx.doi.org/10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L; PMID: 10898340
   PubMedGoogle Scholar
• McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009; 12:35 - 46; http://dx.doi.org/10.1007/s10456-008-9127-z; PMID: 19105036
   PubMed Web of Science ®Google Scholar
• Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS, et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 2007; 109:1495 - 502; http://dx.doi.org/10.1182/blood-2006-06-029298; PMID: 17038532
   PubMed Web of Science ®Google Scholar
• Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003; 278:39548 - 57; http://dx.doi.org/10.1074/jbc.M300539200; PMID: 12893832
   PubMed Web of Science ®Google Scholar
• Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, et al. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003; 10:218 - 29; http://dx.doi.org/10.1038/sj.cdd.4401131; PMID: 12700650
   PubMed Web of Science ®Google Scholar
• Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24:182 - 95; http://dx.doi.org/10.1359/jbmr.081112; PMID: 19016581
   PubMed Web of Science ®Google Scholar
• Costa L, Harper P, Coleman RE, Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 2011; 77:Suppl 1 S31 - 7; http://dx.doi.org/10.1016/S1040-8428(11)70006-3; PMID: 21353179
   PubMedGoogle Scholar
• Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest 2011; 29:533 - 41; http://dx.doi.org/10.3109/07357907.2011.605413; PMID: 21843051
   PubMed Web of Science ®Google Scholar
• Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34:453 - 75; http://dx.doi.org/10.1016/j.ctrv.2008.02.004; PMID: 18423992
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009; 41:721 - 9; http://dx.doi.org/10.1055/s-0029-1224109; PMID: 19536731
   PubMed Web of Science ®Google Scholar
• Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, et al. Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer 2008; 16:209 - 14; http://dx.doi.org/10.1007/s00520-007-0315-y; PMID: 17701225
   PubMed Web of Science ®Google Scholar
• Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 2001; 84:1586 - 90; http://dx.doi.org/10.1054/bjoc.2001.1832; PMID: 11401309
   PubMed Web of Science ®Google Scholar